Navigation Links
Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
Date:10/14/2011

RICHMOND, Calif., Oct. 14, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 9:30 am ET on Friday, October 21, 2011 at the 18th Annual Newsmakers in the Biotech Industry Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. Sangamo has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
2. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
3. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
4. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. Sangamo Announces Pricing of Public Offering of Common Stock
7. Sangamo Announces Public Offering of Common Stock
8. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
9. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
10. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
11. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017   Biostage, Inc. (Nasdaq: ... developing bioengineered organ implants to treat cancers and other ... today the closing on February 15, 2017 of its ... stock and warrants to purchase 20,000,000 shares of common ... offering was priced at $0.40 per share of common ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... Dr. Kingsley Chin, professor and Harvard trained surgeon, completed the procedure on Monday, ... on a 55-year-old practicing female physician suffering from degenerative disc disease with radiculomyelopathy, ...
(Date:2/15/2017)... ... , ... Executive search firm, Slone Partners, announces the placement ... is a veteran life sciences and molecular diagnostics executive with extensive commercialization experience. ... disease risk in future generations. In his new role, Matt will be responsible ...
(Date:2/15/2017)... WARRINGTON, Pa. , Feb. 15, 2017 /PRNewswire/ ... ), a biotechnology company focused on developing aerosolized ... that it has completed a $10.5 million private ... expects that it has sufficient capital to fund ... 2b clinical trial data release in mid-2017. ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
Breaking Biology News(10 mins):